Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although YKL-40 expression is up-regulated in glioblastoma multiforme, its regulation and functions in nontransformed cells of the central nervous system are widely unexplored.
|
21953450 |
2011 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Findings presented in our study showed that increased mRNA level of CHI3L1 could be associated with the progression of astrocytoma and poor patient survival not only for glioblastoma, but for lower grade astrocytoma tumors as well.
|
27121858 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM.
|
26212701 |
2016 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab.
|
29467925 |
2018 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 expression was higher in GBMs than AOs (P < 0.0001) and among GBMs, YKL-40 expression was lower in tumors with either EGFR amplification (P = 0.005) or elevated EGFR expression (P = 0.001).
|
20224722 |
2010 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Astrogliosis Releases Pro-Oncogenic Chitinase 3-Like 1 Causing MAPK Signaling in Glioblastoma.
|
31561550 |
2019 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In glioblastoma metastasis, the malignant mGSC cells express markers of mesenchymal GSC subtype (MES-GSC), such as CD44 and YK-40 and their major obstacle seems to be propagating in the in various organs' microenvironments, different from the niches that home GSCs in the primary glioblastoma.
|
31654711 |
2020 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stepwise multivariate Cox proportional hazards models were used, and the prognostic factors to significantly impact OS were: PFS < 54 weeks (HR: 5.86; CI: 3.02-11.33; p = 0.00); radiotherapy (HR: 0.34; CI: 0.18-0.60; p = 0.00); radio- and chemotherapy (HR: 0.05; CI: 0.03-0.10; p = 0.0), and YKL-40+ GBs (HR: 1.61; CI: 1.28-2.31; p = 0.01).
|
27179219 |
2016 |
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
YKL-40 staining in situ was more abundant in glioblastoma tissue than in anaplastic astrocytoma, with the lowest level in normal brain tissue.
|
25629266 |
2014 |
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Phospho-c-Jun activation by Anisomycin treatment in primary glioblastoma-derived cells attenuates the aggressive features of mesenchymal glioblastomas and leads to promoter methylation and downregulation of key mesenchymal genes (CD44, MMP9 and CHI3L1).
|
28036297 |
2017 |
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001).
|
27090900 |
2017 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis of glioma samples for YKL-40 protein levels revealed substantial elevation in approximately 65% of GBMs and undetectable levels in lower-grade gliomas (grade II and III) or normal brain tissue.
|
12154041 |
2002 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CHI3L2, IL1B, PI3/elafin and CHI3L1, which encodes for YKL-40, a putative prognosticator for various diseases, including cancer, were strongly up-regulated in avascular glioma.
|
18092325 |
2008 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Relative YKL-40 expression was compared with glioma class, key molecular alterations, and immunohistochemical markers via a series of Spearman rank correlations.
|
20224722 |
2010 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, these results suggest that CHI3L1 plays an important role in the regulation of malignant transformation and local invasiveness in gliomas.
|
20506295 |
2011 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2.
|
18708058 |
2008 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40.
|
21953450 |
2011 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our gene analysis revealed that in general, YKL40 mRNA in glioma patients was over-expressed versus normal brain.
|
25629266 |
2014 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Analysis of The Cancer Genome Atlas confirmed a relationship between glioma NF1 status and ENG and CHI3L1 in tumor samples.
|
29643433 |
2018 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
YKL-40 may be an attractive target for glioma therapy.
|
20499402 |
2010 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We measured CHI3L1 expression with quantitative real time-polymerase chain reaction (qRT-PCR) in the cohort of 98 patients with different grade glioma: 10 grade I pylocytic astrocytomas, 30 grade II diffuse astrocytomas, 20 grade III anaplastic astrocytomas, and 38 grade IV astrocytomas (glioblastomas).
|
27121858 |
2016 |
Glioma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that in pediatric high-grade gliomas: (i) histological grading does not have strong prognostic significance, (ii) YKL-40 overexpression is less frequent than adult high-grade gliomas and does not correlate with a more aggressive behavior, (iii) TP53 mutations but not p53 expression may correlate with a more aggressive behavior, and (iv) IDH1 mutations are absent.
|
20174854 |
2010 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate, in a small series of three GCAs, the expression of mesenchymal/radioresistance-associated biomarkers [such as chitinase-3-like protein 1 (YKL-40), hepatocyte growth factor receptor (c-Met), and caveolin 1 (Cav1)] that could contribute to the poor outcome associated with this glioma subgroup.
|
26845757 |
2016 |
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results suggest that the STAT3 pathway is associated with the mTOR downstream pathway mediated by YKL-40 protein, and the combination therapy of the STAT3 inhibitor and rapamycin could be worth developing as a novel therapeutic approach against TMZ-resistant relapsed gliomas.
|
28031240 |
2017 |
Glioblastoma Multiforme
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001).
|
27090900 |
2017 |